Gate Bioscience

A protein is about to leave a cell. It has been folded, tagged, and queued for the exit. In a healthy body this is housekeeping. In a sick one, it is the first step toward damage. Gate Bioscience builds the thing that meets that protein at the door and refuses to let it out.

01 / WHO THEY ARE NOWThe company at the door

Gate Bioscience is a preclinical biotech in Brisbane, California, roughly forty-two people deep, and freshly funded. In November 2025 it closed a $65 million oversubscribed Series B, led by Forbion, with Eli Lilly joining as a strategic investor. That capital is not for a moonshot slide deck. It is to push the company's lead drug programs through IND-enabling studies and into Phase 1 trials - the unglamorous, expensive part where ideas either survive contact with a human body or do not.

What makes them worth a second look is not the round. It is the premise. Gate calls its drugs Molecular Gates, and they do something most medicines do not even attempt: they stop a disease-causing protein from being secreted in the first place.

02 / THE PROBLEM THEY SAWThe proteins medicine keeps missing

Here is the inconvenient fact at the center of a lot of disease: many of the proteins doing the harm are extracellular. They are secreted out of the cell and into circulation, where they drive inflammation, neurodegeneration, and autoimmunity. There are more than 4,000 such proteins in the human body.

Today's tools are good but incomplete. Antibodies can catch a secreted protein once it is already outside, which means you are mopping the floor while the tap runs. Small molecules, which make up the majority of approved drugs and have the bonus of being swallowable, often cannot get a grip on these targets at all. The industry has a polite word for proteins it cannot reach: undruggable. It is less a scientific category than an admission.

The gap is real. A target can be the obvious villain in a disease and still sit untouched for decades because nobody has a molecule that works on it. Gate's founders looked at that and asked a different question - not how do we grab this protein, but where do all of these proteins have to be at some point?

03 / THE FOUNDERS' BETOne door, every protein

The answer turned out to be a chokepoint. Every protein a cell secretes passes through a single channel on its way out, the secretory translocon, anchored by a protein called Sec61. Thousands of different cargoes, one shared exit. Biology built a turnstile and Gate decided to put a guard on it.

The bet, placed in 2021: design small molecules that bind that channel and selectively block a chosen disease protein from passing through. The blocked protein never reaches circulation. Instead, the cell's own cleanup machinery degrades it. You do not chase the villain across the body. You stop it from leaving the building, then let the janitor handle the rest.

The translocon was, for a long time, a textbook diagram - a thing you learned about in cell biology and then forgot. Sharp's academic work suggested it could be perturbed with chemistry. Gate's wager is that "perturbed in a lab" can become "selectively drugged in a patient." Those are very different sentences, separated by a great deal of money and time.

04 / THE PRODUCTA pill that deletes a protein

A Molecular Gate is an oral small molecule. That word "oral" is doing real work - it means a therapy that could, in principle, be a pill rather than an infusion. The molecule binds Sec61, recognizes a specific cargo protein, and blocks that one protein's exit while leaving the thousands of others to pass. Selectivity is the entire game; a guard who stops everyone is just a locked door.

The strategic payoff is that the platform compounds. Gate describes it as a drug discovery engine: each protein the team learns to gate teaches the system something that makes the next target easier. That is the kind of self-reinforcing loop investors love and competitors fear, because it means the moat widens with use.

Two ways to use it follow naturally. Gate runs its own pipeline toward the clinic, and it offers the engine to biopharma partners who have a protein they cannot otherwise touch. The therapeutic focus sits where extracellular proteins cause the most trouble: immunology, inflammatory disease, and neuroscience.

05 / THE PROOFWho is betting, and how much

For a preclinical company, "proof" is mostly the quality of the people writing checks and the science that convinced them. On both counts Gate has a strong table. The Series A drew Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. The Series B added Forbion as lead and, notably, Eli Lilly - a large pharma putting strategic money into a modality it presumably wants a window into.

06 / THE MISSIONEliminate the protein at its source

Stated plainly, Gate's mission is to eliminate disease-causing proteins at their source. The phrase "at their source" is the whole philosophy. Most therapies intervene downstream, after the harmful protein is already loose. Gate intervenes upstream, inside the cell, at the moment of departure. It is the difference between flood insurance and a closed valve.

If the modality works as designed, it does not just produce one drug. It reopens a long list of targets that the field had quietly shelved as too hard. That is the ambition hiding under the careful preclinical language: not a product, a category.

07 / WHY IT MATTERS TOMORROWThe wager that has to clear the clinic

None of this is settled. Gate is preclinical, which means the most important data does not exist yet. A mechanism that is elegant in cells can disappoint in animals, and a drug that works in animals can stumble in people. The next few years - the IND-enabling studies, the first humans dosed - are where the thesis gets graded.

But the shape of the bet is unusually clean. There is one channel. Thousands of targets run through it. If you can put a selective guard on that channel and turn it into a pill, you have not improved an existing class of medicine - you have added a new one. That is rare, and rarity is exactly what the investors named when they wrote their checks.

So return to the door. A protein is about to leave a cell, on its way to do harm somewhere in the body. For most of the history of medicine, the honest answer was to wait downstream and try to catch it. Gate Bioscience is building the thing that meets it at the threshold and says, simply, not today. Whether that holds up in a human being is the question the next chapter has to answer. For now, the door has a guard, and the guard has $135 million and a plan.